{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:40:19Z","timestamp":1761237619604},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,3,22]],"date-time":"2009-03-22T00:00:00Z","timestamp":1237680000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s11899-009-0010-9","type":"journal-article","created":{"date-parts":[[2009,3,21]],"date-time":"2009-03-21T05:45:21Z","timestamp":1237614321000},"page":"66-73","source":"Crossref","is-referenced-by-count":20,"title":["Chronic myelogenous leukemia stem cells: What\u2019s new?"],"prefix":"10.1007","volume":"4","author":[{"given":"Mhairi","family":"Copland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,22]]},"reference":[{"key":"10_CR1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"J.D. Rowley","year":"1973","unstructured":"Rowley JD: Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290\u2013293.","journal-title":"Nature"},{"key":"10_CR2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc2368","volume":"8","author":"M. Savona","year":"2008","unstructured":"Savona M, Talpaz M: Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 2008, 8:341\u2013350.","journal-title":"Nat Rev Cancer"},{"key":"10_CR3","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood.V91.7.2406","volume":"91","author":"J.C. Wang","year":"1998","unstructured":"Wang JC, Lapidot T, Cashman JD, et al.: High level engraftment of NOD\/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 1998, 91:2406\u20132414.","journal-title":"Blood"},{"key":"10_CR4","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","volume":"94","author":"T. Holyoake","year":"1999","unstructured":"Holyoake T, Jiang X, Eaves C, Eaves A: Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999, 94:2056\u20132064.","journal-title":"Blood"},{"key":"10_CR5","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M. Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, et al.: Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction. Blood 2006, 107:4532\u20134539.","journal-title":"Blood"},{"key":"10_CR6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"S.M. Graham","year":"2002","unstructured":"Graham SM, Jorgensen HG, Allan E, et al.: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99:319\u2013325.","journal-title":"Blood"},{"key":"10_CR7","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","volume":"109","author":"H.G. Jorgensen","year":"2007","unstructured":"Jorgensen HG, Allan EK, Jordanides NE, et al.: Nilotinib exerts equipotent anti-proliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007, 109:4016\u20134019.","journal-title":"Blood"},{"key":"10_CR8","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","volume":"111","author":"H. Konig","year":"2008","unstructured":"Konig H, Holyoake TL, Bhatia R: Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src\/Abl kinase inhibitor SKI-606. Blood 2008, 111:2329\u20132338.","journal-title":"Blood"},{"key":"10_CR9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"C.H. Jamieson","year":"2004","unstructured":"Jamieson CH, Ailles LE, Dylla SJ, et al.: Granulocytemacrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004, 351:657\u2013667.","journal-title":"N Engl J Med"},{"key":"10_CR10","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"B.J. Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408\u20132417.","journal-title":"N Engl J Med"},{"key":"10_CR11","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H. Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542\u20132551.","journal-title":"N Engl J Med"},{"key":"10_CR12","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M. Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531\u20132541.","journal-title":"N Engl J Med"},{"key":"10_CR13","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"T.P. Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, et al.: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423\u20131432.","journal-title":"N Engl J Med"},{"key":"10_CR14","doi-asserted-by":"crossref","first-page":"82a","DOI":"10.1182\/blood-2004-03-1134","volume":"104","author":"S. Branford","year":"2004","unstructured":"Branford S, Rudzki Z, Grigg A, et al.: BCR-ABL levels continue to decrease up to 42 months after commencement of standard dose imatinib in patients with newly diagnosed chronic phase CML who achieve a molecular response. Blood 2004, 104:82a.","journal-title":"Blood"},{"key":"10_CR15","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","volume":"101","author":"R. Bhatia","year":"2003","unstructured":"Bhatia R, Holtz M, Niu N, et al.: Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003, 101:4701\u20134707.","journal-title":"Blood"},{"key":"10_CR16","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1084\/jem.20072316","volume":"205","author":"L.L. Zhou","year":"2008","unstructured":"Zhou LL, Zhao Y, Ringrose A, et al.: AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem\/progenitor cells. J Exp Med 2008, 205:2657\u20132671.","journal-title":"J Exp Med"},{"key":"10_CR17","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1182\/blood-2003-11-4026","volume":"103","author":"X. Jiang","year":"2004","unstructured":"Jiang X, Zhao Y, Chan WY, et al.: Deregulated expression in Ph+ human leukemias of AHI-1, a gene activated by insertional mutagenesis in mouse models of leukemia. Blood 2004, 103:3897\u20133904.","journal-title":"Blood"},{"key":"10_CR18","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/nature07016","volume":"453","author":"K. Ito","year":"2008","unstructured":"Ito K, Bernardi R, Morotti A, et al.: PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008, 453:1072\u20131078.","journal-title":"Nature"},{"key":"10_CR19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-07-0042","volume":"7","author":"L. Jin","year":"2008","unstructured":"Jin L, Tabe Y, Konoplev S, et al.: CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 2008, 7:48\u201358.","journal-title":"Mol Cancer Ther"},{"key":"10_CR20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1084\/jem.20072513","volume":"205","author":"Y. Nie","year":"2008","unstructured":"Nie Y, Han YC, Zou YR: CXCR4 is required for the quiescence of primitive hematopoietic cells. J Exp Med 2008, 205:777\u2013783.","journal-title":"J Exp Med"},{"key":"10_CR21","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1158\/0008-5472.CAN-04-2152","volume":"65","author":"J.F. Geay","year":"2005","unstructured":"Geay JF, Buet D, Zhang Y, et al.: p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res 2005, 65:2676\u20132683.","journal-title":"Cancer Res"},{"key":"10_CR22","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1182\/blood-2007-05-090472","volume":"111","author":"A.M. Eiring","year":"2008","unstructured":"Eiring AM, Neviani P, Santhanam R, et al.: Identification of novel posttranscriptional targets of the BCR\/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR\/ABL leukemogenesis. Blood 2008, 111:816\u2013828.","journal-title":"Blood"},{"key":"10_CR23","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1158\/1078-0432.CCR-06-2320","volume":"13","author":"D. Perrotti","year":"2007","unstructured":"Perrotti D, Neviani P: From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way. Clin Cancer Res 2007, 13:1638\u20131642.","journal-title":"Clin Cancer Res"},{"key":"10_CR24","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","volume":"12","author":"C. Zhao","year":"2007","unstructured":"Zhao C, Blum J, Chen A, et al.: Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007, 12:528\u2013541.","journal-title":"Cancer Cell"},{"key":"10_CR25","doi-asserted-by":"crossref","first-page":"17967","DOI":"10.1073\/pnas.0808303105","volume":"105","author":"Y. Minami","year":"2008","unstructured":"Minami Y, Stuart SA, Ikawa T, et al.: BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci U S A 2008, 105:17967\u201317972.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10_CR26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/leu.2008.262","volume":"23","author":"Y. Hu","year":"2009","unstructured":"Hu Y, Chen Y, Douglas L, Li S: Beta-catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009, 23:109\u2013116.","journal-title":"Leukemia"},{"key":"10_CR27","doi-asserted-by":"crossref","first-page":"238a","DOI":"10.1182\/blood.V110.11.775.775","volume":"110","author":"A. Abrahamsson","year":"2007","unstructured":"Abrahamsson A, Geron I, Gotlib J, et al.: Missplicing of glycogen synthase kinase 3 beta: a potential mechanism of blast crisis chronic myeloid leukemia stem cell generation [abstract]. Blood 2007, 110:238a\u2013239a.","journal-title":"Blood"},{"key":"10_CR28","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1182\/blood-2007-05-088815","volume":"110","author":"M.L. Guzman","year":"2007","unstructured":"Guzman ML, Li X, Corbett CA, et al.: Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood 2007, 110:4436\u20134444.","journal-title":"Blood"},{"key":"10_CR29","doi-asserted-by":"crossref","first-page":"74a","DOI":"10.1182\/blood-2005-10-4004","volume":"108","author":"E. Kavalerchik","year":"2006","unstructured":"Kavalerchik E, Gotlib J, Geron I, et al.: Inhibition of chronic myelogenous leukemia stem cells with novel WNT antagonists [abstract]. Blood 2006, 108:74a.","journal-title":"Blood"},{"key":"10_CR30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","volume":"14","author":"C. Dierks","year":"2008","unstructured":"Dierks C, Beigi R, Guo GR, et al.: Expansion of Bcr-Ablpositive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008, 14:238\u2013249.","journal-title":"Cancer Cell"},{"key":"10_CR31","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"J.P. Radich","year":"2006","unstructured":"Radich JP, Dai H, Mao M, et al.: Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006, 103:2794\u20132799.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10_CR32","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood-2007-09-112573","volume":"111","author":"M. Copland","year":"2008","unstructured":"Copland M, Pellicano F, Richmond L, et al.: BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008, 111:2843\u20132853.","journal-title":"Blood"},{"issue":"Suppl1","key":"10_CR33","first-page":"121","volume":"141","author":"F. Pellicano","year":"2008","unstructured":"Pellicano F, Copland M, Jorgensen H, et al.: The farnesyltransferase inhibitor BMS-214662 selectively targets primary CML stem cells through activation of caspases [abstract]. Br J Haematol 2008, 141(Suppl 1):121.","journal-title":"Br J Haematol"},{"key":"10_CR34","doi-asserted-by":"crossref","first-page":"312a","DOI":"10.1182\/blood.V110.11.1031.1031","volume":"110","author":"A.C. Strauss","year":"2007","unstructured":"Strauss AC, Chu S, Holyoake T, Bhatia R: Effective induction of apoptosis in chronic myeloid leukemia CD34+ cells by the histone deacetylase inhibitor LAQ824 in combination with imatinib [abstract]. Blood 2007, 110:312a.","journal-title":"Blood"},{"key":"10_CR35","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.1038\/sj.onc.1207893","volume":"23","author":"A. Burgess","year":"2004","unstructured":"Burgess A, Ruefli A, Beamish H, et al.: Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004, 23:6693\u20136701.","journal-title":"Oncogene"},{"key":"10_CR36","doi-asserted-by":"crossref","first-page":"77a","DOI":"10.1182\/blood.V112.11.189.189","volume":"112","author":"P. Neviani","year":"2008","unstructured":"Neviani P, Santhanam R, Ma Y, et al.: Activation of PP2A by FTY720 inhibits survival and self-renewal of the Ph(+) chronic myelogenous leukemia (CML) CD34+\/CD38- stem cell through the simultaneous suppression of BCR\/ABL and BCR\/ABL-independent signals [abstract]. Blood 2008, 112:77a.","journal-title":"Blood"},{"key":"10_CR37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","volume":"8","author":"P. Neviani","year":"2005","unstructured":"Neviani P, Santhanam R, Trotta R, et al.: The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein. Cancer Cell 2005, 8:355\u2013368.","journal-title":"Cancer Cell"},{"key":"10_CR38","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2007-02-073031","volume":"110","author":"S.J. Neering","year":"2007","unstructured":"Neering SJ, Bushnell T, Sozer S, et al.: Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood 2007, 110:2578\u20132585.","journal-title":"Blood"},{"key":"10_CR39","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.1371\/journal.pone.0000990","volume":"2","author":"N.L. Komarova","year":"2007","unstructured":"Komarova NL, Wodarz D: Effect of cellular quiescence on the success of targeted CML therapy. PLoS ONE 2007, 2:e990.","journal-title":"PLoS ONE"},{"key":"10_CR40","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F. Michor","year":"2005","unstructured":"Michor F, Hughes TP, Iwasa Y, et al.: Dynamics of chronic myeloid leukaemia. Nature 2005, 435:1267\u20131270.","journal-title":"Nature"},{"key":"10_CR41","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","volume":"12","author":"I. Roeder","year":"2006","unstructured":"Roeder I, Horn M, Glauche I, et al.: Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006, 12:1181\u20131184.","journal-title":"Nat Med"},{"key":"10_CR42","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","volume":"105","author":"S. Chu","year":"2005","unstructured":"Chu S, Xu H, Shah NP, et al.: Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005, 105:2093\u20132098.","journal-title":"Blood"},{"key":"10_CR43","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.leu.2404554","volume":"21","author":"D.W. Sherbenou","year":"2007","unstructured":"Sherbenou DW, Wong MJ, Humayun A, et al.: Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia 2007, 21:489\u2013493.","journal-title":"Leukemia"},{"key":"10_CR44","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jnci\/djk150","volume":"99","author":"X. Jiang","year":"2007","unstructured":"Jiang X, Saw KM, Eaves A, Eaves C: Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007, 99:680\u2013693.","journal-title":"J Natl Cancer Inst"},{"key":"10_CR45","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","volume":"21","author":"X. Jiang","year":"2007","unstructured":"Jiang X, Zhao Y, Smith C, et al.: Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007, 21:926\u2013935.","journal-title":"Leukemia"},{"key":"10_CR46","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","volume":"108","author":"N.E. Jordanides","year":"2006","unstructured":"Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC: Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006, 108:1370\u20131373.","journal-title":"Blood"},{"key":"10_CR47","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","volume":"14","author":"D.K. Hiwase","year":"2008","unstructured":"Hiwase DK, Saunders V, Hewett D, et al.: Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008, 14:3881\u20133888.","journal-title":"Clin Cancer Res"},{"key":"10_CR48","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.leu.2404638","volume":"21","author":"C. Brendel","year":"2007","unstructured":"Brendel C, Scharenberg C, Dohse M, et al.: Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007, 21:1267\u20131275.","journal-title":"Leukemia"},{"key":"10_CR49","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"R.A. Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, et al.: Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111:4022\u20134028.","journal-title":"Blood"},{"key":"10_CR50","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S. Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, et al.: Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3496\u20133499.","journal-title":"Blood"},{"key":"10_CR51","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-03-1484","volume":"64","author":"N.J. Donato","year":"2004","unstructured":"Donato NJ, Wu JY, Stapley J, et al.: Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004, 64:672\u2013677","journal-title":"Cancer Res"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0010-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-009-0010-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0010-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T00:32:57Z","timestamp":1589675577000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-009-0010-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,22]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1007\/s11899-009-0010-9","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,22]]}}}